Entero Healthcare Solutions Ltd Share Price
As on 13 June 2026 at 02:37 IST
Entero Healthcare Q1 FY26 Results:
Profit for the period increased 38.4% to ₹27.8 crores in Q1 FY26, from ₹20.1 crores in Q1 FY25. Total income for the quarter increased 26.9% year-on-year to ₹1,409.6 crores, from ₹1,110.5 crores.
About Entero Healthcare Solutions Ltd
Entero Healthcare was founded in the year 2018. It is one of India’s largest and fastest-growing healthcare products distribution platforms. Its headquarters are located at Unit No. 605 & 606, 6th Floor of Trade Center, Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra. The company provides a wide range of healthcare products, including pharmaceuticals and medical devices. It also provides over-the-counter medications. Entero Healthcare falls under the healthcare distribution sector. The company uses technology-driven solutions and a robust network. With these, it ensures efficient and timely delivery of healthcare products across India. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-9.48%
Over 6 Months
10.89%
Over 1 Year
-7.48%
Over 3 Years
-2.89%
Entero Healthcare Solutions Ltd Summary
Close ₹1,116.30
Open ₹1,140
High ₹1,140
Low ₹1,111.50
Volume 46,043
Net Turnover (in Cr) ₹5.16
52Wk High ₹1,390
52Wk Low ₹944
52Wk High / Low
944
1,390
Entero Healthcare Solutions Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹4,857.93
EPS (TTM) 6.90
Book Value (BV) 386.75
Div. Yield -
P/E (TTM) 180.96
Price/Book Value 2.89
Delivery % 46.81 %
Face Value 10
Key Ratios
PE Ratio 257.72
PB Ratio 3
EV to Sales 11.72
PEG Ratio -5.14
ROA 1.14
ROE 3.15
Debt-Equity 0.01
Net Profit Margin 12.90
Operating Profit Margin 20.50
Entero Healthcare Solutions Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 5,135.28 | 3,936.72 | 3,305.72 | 2,526.55 | 1,783.67 |
| Total Expenses | 4,996.55 | 3,901.17 | 3,309.41 | 2,546.36 | 1,794.51 |
| Profit Before Tax | 138.74 | 35.55 | -3.69 | -19.81 | -10.84 |
| Profit After Tax | 107.43 | 39.80 | -11.10 | -29.44 | -15.35 |
| Operating Profit After Depreciation | 180.36 | 101.24 | 45.28 | 9.17 | 9.20 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 559.55 | 289.34 | 267.73 | 262.02 | 190.81 |
| Total Non Current Assets | 626.81 | 334 | 285.56 | 275.10 | 200.35 |
| Total Current Assets | 2,075.71 | 2,010.97 | 1,023.17 | 850.88 | 635.61 |
| Total Assets | 2,702.51 | 2,344.97 | 1,308.73 | 1,125.98 | 835.97 |
| Total Shareholder's Fund | 1,724.14 | 1,638.06 | 595.03 | 561.04 | 485.37 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | -76.87 | -36.61 | -45.32 | -35.27 | -68.68 |
| Net Cash Used In Investing Activities | 232.16 | -704.04 | -48.60 | -161.73 | -30.87 |
| Net Cash Used In Financing Activities | -73.66 | 862.94 | 72.76 | 211.19 | 88.71 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 523.04 | 408.09 | 230.26 | 164.16 | 128.30 |
| Total Expenses | 449.18 | 383.72 | 242.71 | 205 | 146.45 |
| Profit Before Tax | 26.78 | 24.36 | -12.46 | -40.85 | -18.15 |
| Profit After Tax | 19.18 | 38.44 | -12.46 | -40.85 | -18.15 |
| Operating Profit After Depreciation | 75.38 | 46.68 | -1.15 | -35.56 | -15.89 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 28.55 | 34.44 | 40.65 | 51.47 | 52.43 |
| Total Non Current Assets | 994.07 | 107.60 | 90.56 | 96.81 | 96.28 |
| Total Current Assets | 809.46 | 1,660.98 | 673 | 557.27 | 436.43 |
| Total Assets | 1,803.53 | 1,768.58 | 763.57 | 654.08 | 532.71 |
| Total Shareholder's Fund | 1,650.38 | 1,626.41 | 583.73 | 551.21 | 486.44 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | -109.02 | -75.65 | -56.91 | -44.70 | -68.20 |
| Net Cash Used In Investing Activities | 207.75 | -762.69 | -58.29 | -68.80 | -7.21 |
| Net Cash Used In Financing Activities | -40.89 | 925.56 | 91.11 | 127.48 | 75.50 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 1,909.93 | 1,706.52 | 1,570.95 | 1,403.82 | 1,339.06 |
| Total Expenses | 1,823.89 | 1,638.74 | 1,508.89 | 1,353.75 | 1,290.15 |
| Profit Before Tax | 57.95 | 40.40 | 44.62 | 36.37 | 37.22 |
| Profit After Tax | 45.13 | 33.88 | 36.60 | 30.23 | 31.42 |
| Operating Profit after Depreciation | 90.05 | 72.39 | 66.85 | 55.90 | 56.20 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 78.93 | 106.74 | 83.22 | 79.35 | 72.30 |
| Total Expenses | 101.47 | 120.62 | 95.81 | 93.06 | 84.24 |
| Profit Before Tax | 12.04 | 1.37 | 7.61 | 9.17 | -35.66 |
| Profit After Tax | 13.42 | 0.81 | 5.70 | 6.96 | -27.81 |
| Operating Profit after Depreciation | 17.42 | 9.37 | 11.64 | 12.58 | 13.93 |
Entero Healthcare Solutions Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 1,105.20
S2 1,094.10
S3 1,076.70
Pivot 1,122.60
R1 1,133.70
R2 1,151.10
R3 1,162.20
Moving Average
20 SMA 1,195.29
50 SMA 1,214.66
100 SMA 1,161.97
200 SMA 1,132.66
Entero Healthcare Solutions Ltd Corporate Actions
No available data
Entero Healthcare Solutions Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Apollo Hospitals Enterprise Ltd | ₹8,495.95 | ₹1,22,158.73 |
| Max Healthcare Institute Ltd | ₹1,008.95 | ₹98,195.43 |
| Fortis Healthcare Ltd | ₹988.95 | ₹74,661.59 |
| Aster DM Healthcare Ltd | ₹814.20 | ₹42,185.41 |
| Narayana Hrudayalaya Ltd | ₹1,861.80 | ₹38,047.89 |
Entero Healthcare Solutions Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| ICICI Pru P.H.D Fund | 1.74% |
| Invesco India ELSS Tax Saver Fund | 1.03% |
| Invesco India Contra Fund | 0.97% |
| Invesco India Aggressive Hybrid Fund | 0.83% |
| HSBC Consumption Fund | 0.73% |
Entero Healthcare Solutions Ltd News
Entero Healthcare Solutions to convene AGM
On 19 August 2026
29 May 2026, 12:22 pm
Entero Healthcare Solutions to discuss results
On 25 May 2026
19 May 2026, 03:04 pm
Entero Healthcare Solutions to hold board meeting
On 12 February 2026
04 Feb 2026, 01:59 pm
Entero Healthcare Solutions to convene board meeting
On 12 November 2025
29 Oct 2025, 02:08 pm
Entero Healthcare Solutions to discuss results
On 8 August 2025
26 Jul 2025, 10:19 am
Entero Healthcare Solutions Ltd Stock Analysis
- Annual revenue for Entero Healthcare Solutions Ltd increased by 28.17% to ₹523.04 crore in FY 2025 from ₹408.09 crore in FY 2024.
- Annual Net Profit for Entero Healthcare Solutions Ltd decreased by 50.10% to ₹19.18 crore in FY 2025 from ₹38.44 crore in FY 2024.
- Promoter Shareholding in Entero Healthcare Solutions Ltd remains unchanged by 0.00% in the most recent quarter, from 52.42% in December 2025 to 52.42% in March 2026.
- Entero Healthcare Solutions Ltd delivered a 1-year return of -7.48% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
- Entero Healthcare Solutions Ltd share price moved up by 1.59% from its previous close of INR ₹1,116.30. The latest Entero Healthcare Solutions Ltd share price is INR ₹1,134.
- Entero Healthcare Solutions Ltd share price today has been at a low of 1,105 and a high of 1,140. Over the past 52 weeks, the Entero Healthcare Solutions Ltd share price has seen a low of 944 and a high of 1,390.
About Entero Healthcare Solutions Ltd
Entero Healthcare is one of India’s largest and fastest-growing healthcare products distribution platforms. It serves as a vital link between healthcare product manufacturers and pharmacies, hospitals, and clinics. Established in 2018, Entero Healthcare’s integrated and technology-driven distribution platform ensures that healthcare products are accessible across India.
It is operating within the healthcare distribution sector. Entero Healthcare boasts a headquarters located at Unit No. 605 & 606, 6th Floor, Trade Center, Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra. The company was founded by Mr. Rajesh Gupta and Mr. Anil Gupta. They continue to play a pivotal role in its management and growth.
Entero Healthcare’s product portfolio includes a wide range of pharmaceuticals, medical devices, and over-the-counter (OTC) medications. This diversified product range enables the company to meet the varying needs of the healthcare industry effectively.
Entero Healthcare is among the top three healthcare products distributors in India in terms of revenue. The promoter shareholding is mainly held at 52.44% by Prabhat Agarwal and family. The company’s registered office is also its headquarters. It works with registrars like Link Intime India Private Limited to manage its operations efficiently.
Here are the top managing promoters of the company:
One of the key impacts of Entero Healthcare is its contribution to the growth and modernization of the healthcare distribution sector. It is providing a comprehensive and integrated platform. The company has helped bridge the gap between manufacturers and end-users. This makes it easier for healthcare providers to access a wide range of products. This has been particularly beneficial in rural and underserved areas, where access to quality healthcare products can be limited.
Entero Healthcare’s strategic acquisitions have further expanded its reach and product offerings. In May 2024, the company completed four acquisitions of healthcare distributors, adding annualized revenue of over Rs. 170 crore. These acquisitions have not only increased Entero’s market share but also enhanced its ability to serve a broader customer base more effectively. This expansion has positioned Entero Healthcare as one of the top three healthcare products distributors in India in terms of revenue.
The company’s focus on technology-driven solutions has also had a positive impact on the healthcare industry. It has implementing advanced systems for inventory management, order processing, and logistics. Entero Healthcare has improved the efficiency and reliability of the distribution process. This has led to better inventory control, reduced wastage, and improved overall customer satisfaction.
Entero Healthcare’s commitment to quality and innovation has earned it a strong reputation in the industry. The company’s diversified product range, which includes pharmaceuticals, medical devices, and over-the-counter medications. This ensures that it can meet the varying needs of healthcare providers. This has made Entero a preferred partner for many manufacturers and distributors, further solidifying its position in the market.
Entero Healthcare’s role in the healthcare sector extends beyond mere distribution. The company’s ability to adapt to the dynamic market conditions and its commitment to innovation have positioned it as a key player in the industry. It ensuring that healthcare products are delivered promptly and efficiently across the country.
Moreover, Entero Healthcare’s strategic partnerships and collaborations with leading pharmaceutical companies and healthcare providers have further strengthened its market position. These alliances have enabled the company to offer a comprehensive range of products. It has catering to the diverse needs of the healthcare sector. The company’s focus on maintaining high standards of quality and compliance has also earned it the trust and loyalty of its clients.
In addition to its operational achievements, Entero Healthcare is committed to corporate social responsibility. The company actively engages in initiatives aimed at promoting health awareness and education. It also aims at supporting various community programs, and contributing to the overall well-being of society. Through these efforts, Entero Healthcare not only enhances its corporate image but also makes a meaningful difference in the lives of people.
Entero Healthcare’s impact on the healthcare distribution sector in India has been profound. Through strategic acquisitions, technological advancements, and a commitment to quality, the company has transformed the way healthcare products are distributed and accessed. Its efforts have not only improved the efficiency of the supply chain but also contributed to the overall growth and modernization of the healthcare industry. As Entero Healthcare continues to expand its reach and enhance its services, its influence on the sector is expected to grow even further.
It is operating within the healthcare distribution sector. Entero Healthcare boasts a headquarters located at Unit No. 605 & 606, 6th Floor, Trade Center, Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra. The company was founded by Mr. Rajesh Gupta and Mr. Anil Gupta. They continue to play a pivotal role in its management and growth.
Entero Healthcare’s product portfolio includes a wide range of pharmaceuticals, medical devices, and over-the-counter (OTC) medications. This diversified product range enables the company to meet the varying needs of the healthcare industry effectively.
Entero Healthcare is among the top three healthcare products distributors in India in terms of revenue. The promoter shareholding is mainly held at 52.44% by Prabhat Agarwal and family. The company’s registered office is also its headquarters. It works with registrars like Link Intime India Private Limited to manage its operations efficiently.
Here are the top managing promoters of the company:
- Sujesh Vasudevan
- Prabhat Agrawal
- Prem Sethi
- Rajesh Shashikant Dalal
- Sandhya Gadkari Sharma
Impact of the Company
Entero Healthcare has made a significant impact on the healthcare distribution landscape in India since its start in 2018. It has leveraged technology and a robust distribution network. The company has successfully connected healthcare product manufacturers with pharmacies, hospitals, and clinics across the country. This has improved the accessibility of essential healthcare products. It has also streamlined the supply chain, ensuring timely delivery and reducing inefficiencies.One of the key impacts of Entero Healthcare is its contribution to the growth and modernization of the healthcare distribution sector. It is providing a comprehensive and integrated platform. The company has helped bridge the gap between manufacturers and end-users. This makes it easier for healthcare providers to access a wide range of products. This has been particularly beneficial in rural and underserved areas, where access to quality healthcare products can be limited.
Entero Healthcare’s strategic acquisitions have further expanded its reach and product offerings. In May 2024, the company completed four acquisitions of healthcare distributors, adding annualized revenue of over Rs. 170 crore. These acquisitions have not only increased Entero’s market share but also enhanced its ability to serve a broader customer base more effectively. This expansion has positioned Entero Healthcare as one of the top three healthcare products distributors in India in terms of revenue.
The company’s focus on technology-driven solutions has also had a positive impact on the healthcare industry. It has implementing advanced systems for inventory management, order processing, and logistics. Entero Healthcare has improved the efficiency and reliability of the distribution process. This has led to better inventory control, reduced wastage, and improved overall customer satisfaction.
Entero Healthcare’s commitment to quality and innovation has earned it a strong reputation in the industry. The company’s diversified product range, which includes pharmaceuticals, medical devices, and over-the-counter medications. This ensures that it can meet the varying needs of healthcare providers. This has made Entero a preferred partner for many manufacturers and distributors, further solidifying its position in the market.
Entero Healthcare’s role in the healthcare sector extends beyond mere distribution. The company’s ability to adapt to the dynamic market conditions and its commitment to innovation have positioned it as a key player in the industry. It ensuring that healthcare products are delivered promptly and efficiently across the country.
Moreover, Entero Healthcare’s strategic partnerships and collaborations with leading pharmaceutical companies and healthcare providers have further strengthened its market position. These alliances have enabled the company to offer a comprehensive range of products. It has catering to the diverse needs of the healthcare sector. The company’s focus on maintaining high standards of quality and compliance has also earned it the trust and loyalty of its clients.
In addition to its operational achievements, Entero Healthcare is committed to corporate social responsibility. The company actively engages in initiatives aimed at promoting health awareness and education. It also aims at supporting various community programs, and contributing to the overall well-being of society. Through these efforts, Entero Healthcare not only enhances its corporate image but also makes a meaningful difference in the lives of people.
Entero Healthcare’s impact on the healthcare distribution sector in India has been profound. Through strategic acquisitions, technological advancements, and a commitment to quality, the company has transformed the way healthcare products are distributed and accessed. Its efforts have not only improved the efficiency of the supply chain but also contributed to the overall growth and modernization of the healthcare industry. As Entero Healthcare continues to expand its reach and enhance its services, its influence on the sector is expected to grow even further.
FAQ’s
What is the share price of Entero Healthcare Solutions Ltd today?
Entero Healthcare Solutions Ltd share price as on 12 Jun 2026 is ₹ 1134.0
What is the Market Cap of Entero Healthcare Solutions Ltd?
The market cap of Entero Healthcare Solutions Ltd stock is ₹4,857.93 Cr.
What is the PE Ratio of Entero Healthcare Solutions Ltd?
The Price to Earnings (P/E) Ratio of Entero Healthcare Solutions Ltd is 257.72
What is the PB Ratio of Entero Healthcare Solutions Ltd?
The Price to Book (P/B) Ratio of Entero Healthcare Solutions Ltd is 3
What is the 52 week high of Entero Healthcare Solutions Ltd Share Price?
The 52 week high of Entero Healthcare Solutions Ltd share price stands at ₹1,390
What is the 52 week low of Entero Healthcare Solutions Ltd Share Price?
The 52 week low of Entero Healthcare Solutions Ltd share price stands at ₹944
How can I buy shares of Entero Healthcare Solutions Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Entero Healthcare Solutions Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
